You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company and its collaborators previously published a study linking saliva concentrations of multiple microRNAs with concussion duration and symptoms in children.
The five-year initiative aims to collect and disseminate genomic data on 1 million people with Alzheimer's disease or who are at risk for the condition.
A Phase II trial is pursuing molecularly targeted treatments for CUP as a different Phase III trial failed to find benefit for expression-based primary site therapies.
A SUNY Upstate team identified potential PD biomarkers in patients' oral microbiomes, which may lead to a saliva-based assay for early-stage disease.
The firm is validating two biomarkers that it hopes will stratify patients for its investigational drug for pediatric minimally verbal autism.
In a set of new studies, members of an international team mapped gene variation, expression, and regulatory interactions in developing and adult human brains.
The company hopes to develop saliva-based RNA assays for concussion, Parkinson's disease and autism using biomarkers discovered by its two academic partners.
Speakers at the Association of Biomolecular Resource Facilities annual meeting discussed their approaches for single-cell genomic studies of tumor and immune cells.
Gen-Probe (Hologic) has also been awarded
Bio-Rad Laboratories has been awarded US Patent No. 8,236,504, "Systems and methods for fluorescence detection with a movable detection module."
Igor Kordunsky, Jeffrey Goldman, and Michael Finney are named as inventors on the patent.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.